Zoladex

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Advanced Breast CancerRadiation TherapyHigh-Risk Prostate Cancer

39 competitors in Advanced Breast Cancer

#DrugCompanyPhaseTrials

1

Piqray

Novartis

Approved

22

Faslodex

FFresenius Kabi USA, LLC

Approved

63

Kisqali

Novartis

Phase 3

34

Ibrance

Pfizer

Phase 3

35

Verzenio

Eli Lilly

Phase 3

26

Femara

Novartis

Phase 3

27

Aromasin

Pfizer

Phase 3

18

Perjeta

Roche

Phase 3

19

Afinitor

Novartis

Phase 3

110

Herceptin

OOrganon and Co

Phase 3

3Show 27 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Prostate Cancer9 trials

Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer

Completed·—·Phase 2·NCT01250717·28 enrolled

Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer

Completed·Radiation Therapy Oncology Group·Phase 3·NCT00002597·2,028 enrolled

Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg

Unknown status·Luye Pharma Group Ltd.·Phase 1·NCT05856630·24 enrolled

Show 6 more trials

A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer

Completed·Luye Pharma Group Ltd.·Phase 1·NCT03450109·19 enrolled

Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer

Terminated·PPharmatech·Phase 4·NCT02749825·41 enrolled

To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer

Recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT06385847·60 enrolled

Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Completed·Luye Pharma Group Ltd.·Phase 3·NCT04563936·290 enrolled

Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®

Completed·Luye Pharma Group Ltd.·Phase 1·NCT05140512·23 enrolled

Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Recruiting·CCancer Research Antwerp·Phase 2/3·NCT06282588·493 enrolled

Breast Cancer7 trials

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

Unknown status·HHoffman Oncology·Phase 1·NCT02626507·18 enrolled

Fulvestrant in Metastatic Breast Cancer

Unknown status·—·Phase 4·NCT03591549·30 enrolled

Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer

Completed·FFudan University·Phase 3·NCT01712893·216 enrolled

Show 4 more trials

A Prospective, Single-Arm Study to Evaluate the Efficacy and Safety of Zoladex 3.6mg Combined With CEF Chemotherapy as Neo-Adjuvant Therapy in Hormone Responsive, Premenopausal, Operable Breast Cancer

Unknown status·TTianjin Medical University·N/A·NCT00488722

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

Completed·Luye Pharma Group Ltd.·Phase 3·NCT05110170·188 enrolled

Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer

Terminated·EEurofarma Laboratorios S.A.·Phase 3·NCT03936933·6 enrolled

To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.

Withdrawn·AstraZeneca·Phase 3·NCT03658213

ART1 trial

A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants

Completed·EMD Serono Research & Development Institute, Inc.·Phase 1·NCT07097259·55 enrolled

Systemic1 trial

Systemic Hormones and Muscle Protein Synthesis

Unknown status·UUniversity of Nottingham·Phase 3·NCT03054168·34 enrolled

Recurrence1 trial

To Prevent Type I-II Myoma After TCRM Recurrence by Gonadotropin-releasing Hormone (GnRH )Analogues or Mifepristone

Unknown status·WWomen's Hospital School Of Medicine Zhejiang University·N/A·NCT05898321·294 enrolled

10 more indications

Endometriosis1 trial

The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.

Completed·AAZ Jan Palfijn Gent·Phase 4·NCT01682642·120 enrolled

Withdrawal1 trial

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

Completed·—·Phase 2·NCT00165399·62 enrolled

Metabolic Syndrome1 trial

Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome

Terminated·MMassachusetts General Hospital·Phase 1·NCT00438321·66 enrolled

Radiation Therapy1 trial

Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT)

Unknown status·UUniversity of British Columbia·N/A·NCT02594072·80 enrolled

Androgen Deprivation Therapy1 trial

Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose

Terminated·NNorwegian School of Sport Sciences·N/A·NCT03440879·23 enrolled

Metastatic Prostate Cancer1 trial

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT02059213·72 enrolled

Women1 trial

Study to Compare the Bioavailability, Safety and Tolerability of XM17 in Healthy, Down Regulated Young Women

Completed·Merck & Co.·Phase 1·NCT02592031·49 enrolled

Advanced Breast Cancer1 trial

Phase 1 Single-arm, Open-label, Multicenter Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in 2 Parallel Cohorts of Premenopausal Women With Early-stage and Advanced Hormone Receptor-positive (HR+) Breast Cancer

Recruiting·TTerSera Therapeutics LLC·Phase 1·NCT07310420·176 enrolled

High-risk Prostate Cancer1 trial

ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study: A Phase III Trial Randomized Trial (PCS XIV)

Not yet recruiting·DDr. Tamim Niazi·Phase 3·NCT07777263·600 enrolled

Unspecified1 trial

Goserline Acetate VS Dienogest in Endometriosi

Unknown status·MMansoura University·Phase 4·NCT05013242·40 enrolled

Details

Drug Info

Related News